Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, therapeutic companies, which develop a wide variety of treatments for ...

3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

Liquidia faced significant legal challenges from United Therapeutics, delaying the market entry of its PAH drug Yutrepia until after Tyvaso's patent expiry in 2025. Despite tentative FDA approval ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...

It started off with Tommy Castellanos and Trever Jackson throwing ... Later on, it's back to the quarterbacks with Jackson, Brock Glenn, Kevin Sperry, and Castellanos all tossing passes.

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm thinks the challenges to owning United in 2025 are ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most profitable biotech stocks to buy right now. With improved market ...